Head-to-head · Cost-Efficiency Index
LVNG RX vs Woodwork
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
LVNG RX
Cost-first shoppers who want price-sensitive shoppers who are comfortable verifying the real charge at checkout given the markdown-style pricing display.
Visit LVNG RXWoodwork
Cost-first shoppers who want grindr users or men already comfortable with the brand who want ED, GLP-1, and peptide/supplement care bundled under one telehealth account.
Visit WoodworkThe verdict
LVNG RX and Woodwork tie on the Cost-Efficiency Index at 51/100, so neither wins outright on the numbers. For most shoppers we'd start with LVNG RX (ranked #400, a hair above #405) — Cost-first shoppers who want price-sensitive shoppers who are comfortable verifying the real charge at checkout given the markdown-style pricing display. But Woodwork is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs LVNG RX.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | LVNG RX | Woodwork |
|---|---|---|
| Cost-Efficiency Index | 51/100 | 51/100 |
| Semaglutide / mo | $149/mo (starting dose, compounded) | $127/mo (starting dose, compounded oral) |
| Tirzepatide / mo | $249/mo (starting dose, compounded) | $199/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $1,788 | $1,524 |
| Tirzepatide / yr (modeled) | $2,988 | $2,388 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #400 | #405 |
LVNG RX
51/100Where the value is
- '$0 if not approved' removes financial risk from a declined consult
- Clear headline pricing for both semaglutide and tirzepatide
- Explicit disclaimer that independent licensed practitioners make all prescribing decisions
The tradeoffs
- Uses strikethrough 'was/now' pricing display that anchors against a higher reference price of unclear provenance
- An unreconciled second price ($99/mo) appears alongside the primary $149/mo headline for semaglutide
Woodwork
51/100Where the value is
- Backed by an established consumer brand (Grindr LLC) with real infrastructure
- Competitive 'from' pricing on both semaglutide ($127/mo) and tirzepatide ($199/mo)
- Oral tablet option available for semaglutide in addition to injections
The tradeoffs
- GLP-1 is a secondary offering -- the platform's primary identity and marketing focus is ED medication, not weight loss
- No named medical director or clinical leadership found on any accessible page
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.